Cartesian Therapeutics, Inc.
RNAC
Rank in Stocks
#18421
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Share Price
$6.27
Last synced: 2026-10-16
Market Cap
$189.70M
Change (1 day)
-4.71%
Change (1 year)
839.61%
Country
US
Trade Cartesian Therapeutics, Inc. (RNAC)
Category
Healthcare
Market Capitalization of Cartesian Therapeutics, Inc.(RNAC)
Market Cap: $189.70M
As of October 2026 Cartesian Therapeutics, Inc. has a market cap of $189.70M. This makes Cartesian Therapeutics, Inc. the world's 18421st most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Cartesian Therapeutics, Inc. from 2016 to 2026
RNAC compared with Top 5 Most Popular stocks
